Treatment of asthma in children with triamcinolone acetonide aerosol

Triamcinolone acetonide aerosol, 100 microgram qid, was administered for 8 wk to 5 steroid-dependent asthmatic children and 10 who had not previously required continual corticosteroid treatment. Symptomatic control and pulmonary function improved in all 15 children despite discontinuation of oral corticosteroids in 3 of the steroid-dependent children. Determination of morning plasma cortisol concentrations disclosed no evidence of substantial adrenal suppression. Satisfactory symptomatic control has subsequently been maintained for 6 to 32 mo with doses of 100 microgram bid to 300 microgram qid without more extreme changes in plasma cortisol concentrations than were observed during the first 8 wk.